ERBB2 and neoplasm: In terms of tumor subtypes, 113 (51.4%) were HR + /HER2−, 33 (15.0%) HR + /HER2 + , 42 (19.1%) HR−/HER2 + and 24 (10.9%) HR−/HER2− (TN).